Treatment of Insulin-Like Growth Factor Deficiency with IGF-I: Studies in Humans

• Studies from the U.S., Europe, Israel and Ecuador have established the long-term efficacy and safety of IGF-I in treatment of patients with Primary IGFD. • While patients with Primary IGFD may be at risk for hypoglycemia, this can be minimized by educating the families and by administering IGF-I at mealtime. • The use of IGF-I in patients with liver disease or diabetes warrants further evaluation.